Toxicological Risk Assessment and Multi-System Health Impacts from Exposure

<p>Part 1: Modern tools and concepts in toxicology testing<br>1. Mixture toxicity evaluation in modern toxicology<br>2. Alternative methods and their role in modern toxicology<br>3. The exposome—a new paradigm for nonanimal toxicology and integrated risk assessment<br>4. In silico toxicology, a robust approach for decision-making in the context of next-generation risk assessment<br>5. Safety science in the 21st century—a scientific revolution in its making<br>6. Chemobrain</p> <p>Part 2: Methods and toxicity models in toxicology<br>7. "Predictive in silico toxicology." An update on modern approaches and a critical analysis of its strong and weak points<br>8. Analytical strategies to study the gut microbiome in toxicology<br>9. Behavioral endpoints in adult and developmental neurotoxicity: the case of organophosphate pesticides<br>10. Nuclear factor erythroid 2-related factor 2-mediated antioxidant response as an indicator of oxidative stress<br>11. The potential of complex in vitro models in pharmaceutical toxicology</p> <p>Part 3: New insights in risk assessment<br>12. Health-based exposure limits and toxicology in pharmaceutical industry<br>13. The hormetic dose response: implications for risk assessment<br>14. Endocrine disruption and human health risk assessment in light of real-life risk simulation<br>15. Toxicity data as the basis for acute and short-term emergency exposure guidance<br>16. Renal mitochondria as sentinels for exposures to environmental toxicants and nephrotoxic drugs</p> <p>Part 4: Clinical biomarkers updates<br>17. Updates on current biomarkers in toxicology<br>18. The role of extracellular matrix in allergic contact dermatitis pathogenesis<br>19. Review of current neurotoxicology issues<br>20. Modern aspects of immunotoxicology<br>21. Toxicology of neurodegenerative diseases<br>22. Toxicogenetics—Pharmacogenetics: genetic variability profiling for xenobiotic response heterogeneity<br>23. Current and emerging concepts of cardiotoxicity<br>24. Metabolomics: diagnostic and therapeutic applications in clinical medicine and pharmacology<br>25. Metabolomics methodology and workflow: challenges and future prospects<br>26. Telomere length: associations with nutrients and xenobiotics</p> <p>Part 5: Epidemiology and public health toxicology issues<br>27. Dismissing the use of P-values and statistical significance testing in scientific research: new methodological perspectives in toxicology and risk assessment<br>28. Modern approaches for the assessment of human exposure to dietary mycotoxins<br>29. Tobacco toxicity and regulatory science<br>30. Dethroning the crown. From the kinetics and dynamics of COVID-19 diagnosis to the promising treatments<br>31. Toxicology issues related to COVID-19 outbreak<br>32. Risk assessment for heat stress during work and leisure</p> <p>Part 6: Pharmaceuticals and nutraceuticals toxicology updates<br>33. Polyphenols: the hallmark of endothelial dysfunction combatants<br>34. Effect of diet, pharmaceuticals, and environmental toxicants on gut microbiota imbalance and increased intestinal membrane permeability<br>35. Hydrogen sulfide: a shifting paradigm<br>36. Redox biomarkers in toxicology and nutrition: the social link<br>37. Safety profile of plants and phytoconstituents used in traditional medicine worldwide</p> <p>Part 7: Toxicology of biomaterials and nanomaterials<br>38. Epigenetic mechanisms in nanomaterial toxicity<br>39. Predictive nanotoxicology: from nanotoxicity to nanosafety of select and commonly used nanomaterials<br>40. The toxicological effects of titanium dioxide nanoparticles on marine microalgae<br>41. Aquatic nanotoxicology: reference species and omics technologies<br> <br>Part 8: Special topics in toxicology<br>42. Toxicity of arsenicals in diseases: friend or foe?<br>43. Toxicity of psychedelic drugs<br>44. Immunotoxicity of pesticides: current knowledge and perspectives<br>45. Glyphosate-based herbicides: evidence of immune-endocrine alteration<br>46. Ciguatera toxins: toxicity and food safety<br>47. Cannabinoids and psychosis: current challenges of mechanistic toxicology<br>48. Electronic cigarettes as a harm reduction concept for public health</p>